Cts Corporation shares rise 1.03% intraday after BD announces first pharma-sponsored clinical trial.

miércoles, 23 de julio de 2025, 10:10 am ET1 min de lectura
CTS--
Cts Corporation rose 1.03% in intraday trading, with the company's stock price movement aligning with the recent news event of BD (Becton, Dickinson and Company) announcing the first pharma-sponsored combination product clinical trial using the BD Libertas™ Wearable Injector for subcutaneous delivery of complex biologics. This news event is positive for the company as it represents a significant advancement in the field of medical technology.

Cts Corporation shares rise 1.03% intraday after BD announces first pharma-sponsored clinical trial.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios